 TRACON Pharmaceuticals Inc NASDAQ:TCON ended the first quarter of 2021 on March 31 with cash and equivalents of 30.4 million, which it said will fund its operations into the second half of 2022. The company also noted that as of May 5, it has initiated 22 US clinical sites and enrolled more than 20 patients in the pivotal ENVASARC trial of single-agent envafolimab and envafolimab combined with Yervoy, which has triggered the initial Data Monitoring Committee review of safety data from each cohort. 